NeuroScientific Biopharmaceuticals reported positive clinical responses in its StemSmart™ Special Access Program for fistulising Crohn’s disease and has initiated manufacturing technology transfer to support Phase 2 trials planned for late 2026.
- Positive clinical responses in 3 of 4 Crohn’s patients
- Manufacturing transfer to Q-Gen Cell Therapeutics underway
- FDA pre-IND engagement shaping Phase 2 trial design
- EmtinB™ glaucoma program faces technical and timeline challenges
- Strong cash position of $5.68 million supports ongoing development
Encouraging Clinical Outcomes in Tough Crohn’s Cohort
NeuroScientific Biopharmaceuticals (ASX:NSB) has reported that three of four patients treated with its StemSmart™ mesenchymal stem cell therapy under the Therapeutic Goods Administration’s Special Access Scheme achieved a significant clinical response in fistulising Crohn’s disease, a notoriously difficult-to-treat condition. The fourth patient showed a partial response, with ongoing assessments continuing. These results reinforce earlier Phase 2 data showing a 78% response rate in refractory Crohn’s patients and bolster confidence in the StemSmart™ platform’s potential.
The patients treated had exhausted all approved therapies prior to StemSmart™, highlighting the unmet medical need this therapy aims to address. This real-world evidence is actively informing the design of the upcoming Phase 2 trial, which is targeted to commence in the second half of 2026. The trial will be conducted across Australia and the United States, focusing on refractory and fistulising Crohn’s disease populations. Early engagement with clinicians and trial sites is underway to establish a robust investigator network capable of efficient patient recruitment and high-quality data generation. This clinical progress builds on earlier momentum from the company’s initial patient treatments under the Special Access Program, as detailed in previous reports such as the StemSmart™ Crohn’s Treatment Program.
Manufacturing Scale-Up Through Technology Transfer to Q-Gen
In parallel with clinical advances, NeuroScientific has initiated the critical technology transfer of StemSmart™ manufacturing to Q-Gen Cell Therapeutics, a GMP-licensed contract manufacturer based in Brisbane. This transfer is essential to scaling production capacity to meet the demands of late-stage clinical trials and eventual commercial supply. The process is progressing through a six-stage program including process mapping, SOP transfer, analytical qualification, and GMP demonstration runs. The current phase involves manufacturing consecutive compliant batches to validate the process under stringent quality standards.
Q-Gen’s 13-cleanroom facility and 25 years of cell therapy manufacturing experience position it well to support NeuroScientific’s clinical and commercial ambitions. The technology transfer is on schedule for completion in the second half of 2026, coinciding with the planned Phase 2 trial start, thereby aligning manufacturing readiness with clinical development timelines. This partnership addresses a common bottleneck in cell therapy programs by securing a reliable and scalable supply chain. The company’s manufacturing progress follows up on earlier strategic moves including its partnership announcements and executive appointments outlined in the manufacturing scale-up partnership.
Regulatory Strategy and FDA Engagement
NeuroScientific is actively preparing for a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA), a pivotal step to refine the Phase 2 study design and regulatory pathway. A comprehensive gap assessment with regulatory advisor Scendea has been completed to benchmark existing data against FDA expectations. Feedback from this meeting will likely influence patient selection, endpoints, dosing strategies, and overall development plans, ensuring alignment with requirements for future late-stage trials.
Real-world data from the Special Access Program is playing a vital role in shaping a patient-centric and pragmatic clinical trial approach. Early discussions with key opinion leaders and clinical centres in both Australia and the U.S. aim to optimize trial execution and build a high-quality investigator network. These preparatory activities underscore the company’s strategic focus on regulatory alignment and global clinical readiness.
EmtinB™ Glaucoma Program Faces Development Hurdles
While StemSmart™ advances, NeuroScientific’s EmtinB™ program targeting glaucoma is encountering significant challenges. Despite promising early-stage non-clinical data demonstrating target engagement and neuroprotective activity, formulation stability issues have delayed progress. None of the tested formulations meet the stringent requirements for intravitreal administration, extending development timelines by 18 to 24 months and increasing technical and commercial risks.
The Board is considering strategic options including out-licensing or partnerships to leverage external expertise in ophthalmic peptide development. This approach could mitigate risks while preserving shareholder value. An update on this program is expected in due course, reflecting ongoing evaluation of its feasibility within NeuroScientific’s portfolio.
Financial Position Supports Ongoing Development
NeuroScientific ended the quarter with a cash balance of approximately A$5.68 million, providing a runway of over eight quarters at current operating cash burn levels. The company continues to manage expenses prudently, with R&D costs around A$385,000 for the quarter and administration costs maintained at approximately A$201,000. Director fees and related party payments totalled about A$98,000.
This financial position supports the company’s clinical and manufacturing activities as it advances StemSmart™ toward commercialisation while managing the complexities of its glaucoma program. The company’s ability to maintain funding without immediate capital raises marks a stable footing amid the capital-intensive nature of biotech development.
Bottom Line?
NeuroScientific’s positive clinical signals and manufacturing scale-up position StemSmart™ well for late 2026 Phase 2 trials, though regulatory feedback and EmtinB™ development risks remain key upcoming factors.
Questions in the middle?
- How will FDA feedback reshape the Phase 2 trial design and regulatory strategy?
- Can Q-Gen’s manufacturing transfer meet validation targets on schedule to support clinical supply?
- What strategic partnerships might emerge for EmtinB™ given its formulation challenges and timeline extensions?